Attached files

file filename
10-Q - 10-Q - T2 Biosystems, Inc.t2-3312017x10qxdocument.htm
EX-31.2 - EXHIBIT 31.2 - T2 Biosystems, Inc.exhibit312-3312017.htm
EX-31.1 - EXHIBIT 31.1 - T2 Biosystems, Inc.exhibit311-3312017.htm
EX-10.4 - EXHIBIT 10.4 - T2 Biosystems, Inc.exhibit104-3312017.htm
EX-10.3 - EXHIBIT 10.3 - T2 Biosystems, Inc.exhibit103-3312017.htm
EX-10.2 - EXHIBIT 10.2 - T2 Biosystems, Inc.exhibit102-3312017.htm
EX-10.1 - EXHIBIT 10.1 - T2 Biosystems, Inc.exhibit101-3312017.htm


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
 
18 U.S.C. SECTION 1350,
 
AS ADOPTED PURSUANT TO
 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of T2 Biosystems, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John McDonough, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
 
 
/s/ John McDonough
 
John McDonough
 
President, Chief Executive Officer and Director
 
(principal executive officer)
 
(principal financial officer)
 
 
Date: May 8, 2017
 
This certification accompanies each Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
 
A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.